Antiangiogenic therapy of transgenic mice impairs de novo tumor growth.
Angiogenesis is activated during multistage tumorigenesis prior to the emergence of solid tumors. Using a transgenic mouse model, we have tested the proposition that treatment with angiogenesis inhibitors can inhibit the progression of tumorigenesis after the switch to the angiogenic phenotype. In this model, islet cell carcinomas develop from multifocal, hyperproliferative nodules that show the histological hallmarks of human carcinoma in situ. Mice were treated with a combination of the angiogenesis inhibitor AGM-1470 (TNP-470), the antibiotic minocycline, and interferon alpha/beta. The treatment regimen markedly attenuated tumor growth but did not prevent tumor formation; tumor volume was reduced to 11% and capillary density to 40% of controls. The proliferation index of tumor cells in treated and control mice was similar, whereas the apoptotic index was doubled in treated tumors. This study shows that de novo tumor progression can be restricted solely by antiangiogenic therapy. The results suggest that angiogenesis inhibitors represent a valid component of anticancer strategies aimed at progression from discrete stages of tumorigenesis and demonstrate that transgenic mouse models can be used to evaluate efficacy of candidate antiangiogenic agents.
Parangi
S
S
Department of Biochemistry and Biophysics, Hormone Research Institute, University of California, San Francisco, CA 94143-0534, USA.
O'Reilly
M
M
Christofori
G
G
Holmgren
L
L
Grosfeld
J
J
Folkman
J
J
Hanahan
D
D
D007516:Adenoma, Islet Cell / Q000188:drug therapy*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D017209:Apoptosis; D002455:Cell Division; D003510:Cyclohexanes; D007370:Interferon Type I / Q000627:therapeutic use*; D051379:Mice; D008822:Mice, Transgenic; D008911:Minocycline / Q000627:therapeutic use*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D016196:S Phase; D012717:Sesquiterpenes / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D007370:Interferon Type I; D012717:Sesquiterpenes; D008911:Minocycline; D000077609:O-(Chloroacetylcarbamoyl)fumagillol